GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of am I the only one who found tirzepatide harder than the injections — 39 comments in the full submission. View in context.
4.9k
c/tirzepatide·submitted 2 years ago by u/kian_ekstrom

am I the only one who found tirzepatide harder than the injections

Discussionbranch of 8 comments

am I the only one who found tirzepatide harder than the injections. I am not trying to be the "source?" guy. I would just like a source. The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to. Vials…

Read the full submission and all 39 comments →

This branch

8 comments, started 2 years ago
u/titration_marshalmod · c/semaglutide159 points·2 years ago

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

replysharereportpermalink
u/kian_ekstromOP68 points·2 years ago

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

replysharereportpermalink
u/britt_okwuosa54 points·2 years ago·edited

I would separate the two claims. That the GIP arm exists is uncontroversial; that it explains your reflux pattern is a guess.

replysharereportpermalink
u/dexa_twice_yearlyMOD96 points·2 years ago

Trial identifiers corrected in the title. SURMOUNT and SURPASS are different programmes.

replysharereportpermalink
u/kian_ekstromOP90 points·2 years ago

That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.

replysharereportpermalink
u/mikkel_ogunleye50 points·2 years ago

Correction to my own post above — I said 5mg and I have been on 2.5mg since the spring. Same argument, wrong number.

replysharereportpermalink
u/fatima_wojcik33 points·2 years ago

Not sure that follows. You went up a step and changed your training in the same fortnight.

replysharereportpermalink
u/rania_marchand10 points·2 years ago

SURMOUNT-1 landed around 21% at 72 weeks on the top arm

replysharereportpermalink

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.